Edwin Moses appointed chair of Dark Blue Therapeutics

Edwin Moses, a veteran pharmaceutical entrepreneur, has been appointed chairman of Dark Blue Therapeutics Ltd, an Oxford University, UK, spinout which is in transition to becoming a clinical stage company. Dr Moses has over 30 years of board level experience in over 20 European life science companies with expertise in drug discovery and development as well as building successful businesses. Among his achievements, Dr Moses built, as CEO, Oxford Asymmetry International plc and Ablynx NV, where he oversaw the whole process for Cablivi, a treatment for a rare blood disorder. He is also chairman of Avantium NV, LabGenius Ltd and NanoSyrinx Ltd. Dark Blue is progressing its lead programme, an oral first-in-class MLLT 1/3 degrader focused on delivering clinical data over the next 24 months, in acute myeloid leukaemia, and also on its programme targeting ADAR1 inhibition to address solid tumours.

Dark Blue announced the appointment on 3 April 2025.